Copy to clipboard 
Native Orthopaedics received FDA 510(k) clearance for the Repair Construct — a knotless, intraoperatively adjustable suture fixation product powered by the company’s two proprietary technologies – Dragonfly finger trap and Zerofly integrated soft button fixation.
Cleared indications include soft tissue-to-bone fixation in the shoulder (biceps tenodesis, AC separation repair), foot and ankle (Achilles tendon repair), and knee (meniscal root repair, MPFL repair, ACL/PCL repair). Native’s initial commercial focus will be on the many types of ACL and PCL repair.
Each Repair Construct is powered by a Dragonfly quad-core advanced finger trap for independent tissue tensioning. The surgeon attaches the Repair Construct to the tissue, shuttles the construct through a bone tunnel, and connects it to Native’s titanium Bow-Tie button, or can select a Repair Construct that is preassembled with the patented Zerofly soft button fixation. Zerofly is a metal free cortical fixation technology designed to conform to the patient’s anatomy, while providing versatility for the surgeon. Once shuttled through the tunnel, simply pull the tail of the Dragonfly to optimize the tension of the construct and reduce the tissue to the bone.
After initial fixation, the surgeon can cycle the joint and pull the tail again to remove additional laxity that may develop from viscoelastic creep. Each construct can be re-tensioned independently without disturbing the rest of the repair.
Dragonfly’s quad-core architecture — a finger trap within a finger trap — doesn’t rely on a secondary locking feature to prevent slippage. The construct is protected by 21 issued patents, with 30+ additional applications pending.
Additionally, Native received a third FDA 510(k) clearance for the Native Bridge – a novel construct intended for the fixation of bone to bone, and is intended as fixation posts, a distribution bridge, or for distributing suture tension over areas of ligament or tendon repair in ACL/PCL repair.
The company’s Native Root System, powered by Dragonfly for meniscal root repair, received FDA marketing clearance in 2025.
Source: Native Orthopaedics
Native Orthopaedics received FDA 510(k) clearance for the Repair Construct — a knotless, intraoperatively adjustable suture fixation product powered by the company's two proprietary technologies - Dragonfly finger trap and Zerofly integrated soft button fixation.
Cleared indications include soft tissue-to-bone fixation in the shoulder (biceps...
Native Orthopaedics received FDA 510(k) clearance for the Repair Construct — a knotless, intraoperatively adjustable suture fixation product powered by the company’s two proprietary technologies – Dragonfly finger trap and Zerofly integrated soft button fixation.
Cleared indications include soft tissue-to-bone fixation in the shoulder (biceps tenodesis, AC separation repair), foot and ankle (Achilles tendon repair), and knee (meniscal root repair, MPFL repair, ACL/PCL repair). Native’s initial commercial focus will be on the many types of ACL and PCL repair.
Each Repair Construct is powered by a Dragonfly quad-core advanced finger trap for independent tissue tensioning. The surgeon attaches the Repair Construct to the tissue, shuttles the construct through a bone tunnel, and connects it to Native’s titanium Bow-Tie button, or can select a Repair Construct that is preassembled with the patented Zerofly soft button fixation. Zerofly is a metal free cortical fixation technology designed to conform to the patient’s anatomy, while providing versatility for the surgeon. Once shuttled through the tunnel, simply pull the tail of the Dragonfly to optimize the tension of the construct and reduce the tissue to the bone.
After initial fixation, the surgeon can cycle the joint and pull the tail again to remove additional laxity that may develop from viscoelastic creep. Each construct can be re-tensioned independently without disturbing the rest of the repair.
Dragonfly’s quad-core architecture — a finger trap within a finger trap — doesn’t rely on a secondary locking feature to prevent slippage. The construct is protected by 21 issued patents, with 30+ additional applications pending.
Additionally, Native received a third FDA 510(k) clearance for the Native Bridge – a novel construct intended for the fixation of bone to bone, and is intended as fixation posts, a distribution bridge, or for distributing suture tension over areas of ligament or tendon repair in ACL/PCL repair.
The company’s Native Root System, powered by Dragonfly for meniscal root repair, received FDA marketing clearance in 2025.
Source: Native Orthopaedics
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
